A Systematic, Patient-Centered Approach to Managing Metastatic Gastric or GEJ Adenocarcinoma
Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.
This activity is supported by an independent education grant from Lilly.
Scroll to the Bottom of this Information to Begin this Course
Release date: December 21, 2017
Valid through: December 21, 2018
Topic: Gastric Cancer
Estimated Time to Complete Activity: 60 minutes
This educational activity is for oncology healthcare providers (HCPs), including physicians, nurses, and PAs who manage patients with locally advanced and metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
The treatment of metastatic gastric and gastroesophageal (GEJ) cancer is evolving with the introduction of several new targeted therapies and immunotherapeutic approaches in recent years. Biomarker testing is essential for selecting the optimal therapy for each patient. Also, it is important to use therapies in a rational sequence in order to maximize the use of all available therapies. Patients should be included as active participants in the decision-making process. This shared decision making ensures that treatment choices align with patients’ preferences, goals, and expectations.
This interactive CME activity allows you to respond to questions, see how you compare with your peers, and provides updates from our Dr Ajani on the latest developments in the treatment of gastric/GEJ cancer.
After completing this activity, the participant will demonstrate the ability to:
- Summarize the pathogenesis and molecular pathways involved in the development and progression of gastric cancer
- Evaluate the safety, efficacy, and quality of data for available and emerging targeted therapies for locally advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma
- Individualize and optimize treatment with sequencing and management of treatment-related adverse events for locally advanced or metastatic gastric and GEJ adenocarcinoma
- Engage patients with locally advanced or metastatic gastric and GEJ adenocarcinoma in their care by implementing effective shared decision making (SDM) strategies
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 contact hours
All other healthcare professionals completing this course will be issued a statement of participation.
Jaffer A. Ajani, MD
Professor of Medicine, Department of Gastrointestinal Medical Oncology
University of Texas MD Anderson Cancer Center
Continuing Education Information
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is awarded 1.0 Contact Hour.
It is the policy of RMEI Medical Education, LLC and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Consulting Fees: Bristol-Myers Squibb, Celgene, Genentech, Insys, Lilly, and Medscape.
- Contracted Research: Bristol-Myers Squibb and Delta-Fly.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Tania Dickson, MD, has no affiliations with commercial interests to disclose.
- Mindy Tanzola, PhD, has no affiliations with commercial interests to disclose.
- Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
- Jessica Hatch, has no affiliations with commercial interests to disclose.
- Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner: has no affiliations with commercial interests to disclose.
- Patricia Brignoni, Sr. Project Manager: has no affiliations with commercial interests to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must read the learning objectives and faculty disclosures; participate in the educational activity; and complete the post-test and the evaluation form. If you pass the post-test and complete the evaluation, your certificate will be available immediately for download in PDF format.
Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at email@example.com.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.
Disclosure of Unlabeled Use and Investigational Products
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.